BeOne Medicines Ltd
234 hedge funds and large institutions have $8.65B invested in BeOne Medicines Ltd in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 79 reducing their positions, and 33 closing their positions.
267% more call options, than puts
Call options by funds: $9.57M | Put options by funds: $2.61M
3% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 79
0% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 33
0.14% less ownership
Funds ownership: 4.13% → 3.99% (-0.14%)
2% less funds holding
Funds holding: 238 → 234 (-4)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
17% less capital invested
Capital invested by funds: $10.4B → $8.65B (-$1.73B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$50.4M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$36.2M |
| 3 |
BlackRock
New York
|
+$25.4M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$17.4M |
| 5 |
UIM
USS Investment Management
London,
United Kingdom
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$136M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$81.4M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$39.2M |
| 4 |
CC
Casdin Capital
New York
|
-$28.3M |
| 5 |
PCIG
Partners Capital Investment Group
Boston,
Massachusetts
|
-$21.1M |
ONC Hedge Fund Activity: Q2 2022 in Review
234 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2022, worth a combined $8.65B — down 17% from $10.4B a quarter earlier.
Fund positioning in ONC was balanced in Q2 2022: 33 funds opened new positions, 33 closed out, 81 added to existing stakes and 79 trimmed.
The largest buyer was Primecap Management, adding an estimated $50.4M. The largest seller was Baillie Gifford & Co, cutting an estimated $136M.
- 234 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2022, down from 238 in Q1 2022.
- Funds reported $8.65B of BeOne Medicines Ltd stock for Q2 2022, down 17% quarter-over-quarter.
- 33 funds opened new BeOne Medicines Ltd positions in Q2 2022 and 33 closed out, a net change of 0 holders.
- The largest BeOne Medicines Ltd buyer in Q2 2022 was Primecap Management, an estimated $50.4M added.
- The largest BeOne Medicines Ltd seller in Q2 2022 was Baillie Gifford & Co, an estimated $136M sold.
Based on aggregated 13F filings for Q2 2022.